BioCentury | Oct 20, 2014
Company News

ContraFect, China CDC deal

...is a combination of human mAbs CF-401 , which targets Type A, group 1 influenza; CF-402...
BioCentury | Nov 22, 2004
Emerging Company Profile

Can-Fite: Muscling up on A3

Building on the observation that tumors rarely spread to muscle tissue, Can-Fite BioPharma Ltd. is developing small molecule adenosine receptor modulators that are active against cancer and inflammatory diseases such as rheumatoid arthritis. The company's...
Items per page:
1 - 2 of 2